{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:33:20Z","timestamp":1767706400709,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:00:00Z","timestamp":1585440000000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.semarthrit.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T09:36:32Z","timestamp":1532079392000},"page":"927-932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-5895","authenticated-orcid":false,"given":"Marc","family":"Scherlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.07.005_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.2015.1090313","article-title":"Biosimilars for the management of rheumatoid arthritis: economic considerations","volume":"11","author":"Gul\u00e1csi","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0002","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0003","first-page":"533","article-title":"Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK","volume":"31","author":"Aladul","year":"2017","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0004","article-title":"Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases","volume":"77","author":"Kay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2018.03.002","article-title":"Biosimilars: an opportunity. Position statement of the french rheumatology society (SFR) and inflammatory rheumatic disease club (CRI)","author":"Schaeverbeke","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0007","article-title":"Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance","author":"Scherlinger","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","article-title":"Treatment outcomes with biosimilars: be aware of the nocebo effect","volume":"4","author":"Rezk","year":"2017","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0010","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0011","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (Part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0012","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117214","article-title":"Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France","volume":"10","author":"Jacomet","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.respe.2007.01.026","article-title":"Des usagers sceptiques face aux m\u00e9dicaments g\u00e9n\u00e9riques\u202f: une approche anthropologique.","volume":"55","author":"Sarradon","year":"2007","journal-title":"Rev Epid\u00e9miologie Sant\u00e9 Publique"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-015-0415-3","article-title":"What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs","volume":"13","author":"Dunne","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2018.03.009","article-title":"The confidence of rheumatologists about switching to biosimilar for their patients","author":"Goll","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0018","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of originator biologics and biosimilars: a survey among belgian rheumatoid arthritis patients and rheumatologists","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2018.07.005_bib0019","first-page":"A262","article-title":"PE0105:biosimilaires en rhumatologie\u202f: information et opinions des rhumatologues hospitaliers fran\u00e7ais, r\u00e9sultats de l\u2019\u00e9tude BRIO","volume":"84","author":"Cohen","year":"2017","journal-title":"Rev Rhum"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0020","unstructured":"Gibofsky A, Badawi S. Biosimilar knowledge among US rheumatologists \u2013 a survey. ACR Meeting Abstracts. Available from: http:\/\/acrabstracts.org\/abstract\/biosimilar-knowledge-among-us-rheumatologists-a-survey\/"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0021","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s11606-007-0284-3","article-title":"Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use","volume":"22","author":"Shrank","year":"2007","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6963-11-17","article-title":"Determinants of generic drug substitution in Switzerland","volume":"11","author":"Decollogny","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0023","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0037-7856(75)90101-8","article-title":"The burden of rheumatoid arthritis: tolerating the uncertainty","volume":"9","author":"Wiener","year":"1975","journal-title":"Soc Sci Med (1967)"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.socscimed.2004.08.005","article-title":"Moral hazard and prescription medicine use in Australia\u2013the patient perspective","volume":"60","author":"Doran","year":"2005","journal-title":"Soc Sci Med (1982)"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","article-title":"Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of cochin university hospital, Paris, France","volume":"47","author":"Avouac","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/art.40516","article-title":"Open-label non-mandatory transitioning from originator etanercept to biosimilar SB4: 6-month results from a controlled cohort study","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/11535360-000000000-00000","article-title":"Impact of european pharmaceutical price regulation on generic price competition: a review","volume":"28","author":"Puig-Junoy","year":"2010","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.semarthrit.2018.07.005_bib0028","unstructured":"Prescribing Costs in Hospitals and the Community, England 2015\/16 - NHS Digital. Available from: http:\/\/digital.nhs.uk\/catalogue\/PUB22302"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:58:07Z","timestamp":1758733087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218302622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0049017218302622"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}